Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 18Leukemia, Myeloid, Acute 15Breast Neoplasms 14Glioblastoma 13Colorectal Neoplasms 13Prostatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Multiple Myeloma 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Ovarian Neoplasms 5Melanoma 5Uterine Cervical Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Solid Tumor 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Advance Solid Tumors × 1 year × Clear all
NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 1 Suspended
16 enrolled
Other solid neoplasm

Advance Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡